SQA
ADAP

Simon Quick Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Simon Quick Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,000
Closed -$3.9K – 391
2025
Q3 		$3.9K Hold
30,000
– – ﹤0.01% 397
2025
Q2 		$7.19K Hold
30,000
– – ﹤0.01% 359
2025
Q1 		$5.91K Hold
30,000
– – ﹤0.01% 610
2024
Q4 		$16.2K Sell
30,000
-452
-1% -$329 ﹤0.01% 491
2024
Q3 		$28.9K Buy
30,452
+452
+2% +$513 ﹤0.01% 437
2024
Q2 		$29.2K Hold
30,000
– – ﹤0.01% 388
2024
Q1 		$47.4K Hold
30,000
– – ﹤0.01% 416
2023
Q4 		$23.8K Buy
+30,000
New +$16.9K ﹤0.01% 343

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Simon Quick Advisors's ADAP Position: Q4 2025 in Review

Simon Quick Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 30,000 shares — an estimated $3.9K sold.

Simon Quick Advisors first reported a position in ADAP in Q4 2023 and held it in 8 quarters. The position peaked at $47.4K in Q1 2024. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Simon Quick Advisors reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Simon Quick Advisors sold 30,000 Adaptimmune Therapeutics shares in Q4 2025, an estimated $3.9K.
  • Simon Quick Advisors first reported a position in Adaptimmune Therapeutics in Q4 2023 and held it in 8 quarters.
  • Simon Quick Advisors's Adaptimmune Therapeutics position peaked at $47.4K in Q1 2024.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Simon Quick Advisors's 13F filing for Q4 2025, filed 29 Jan 2026.